Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Nintedanib Stories

2014-02-24 08:29:21

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2014 /PRNewswire/ -- Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company discovering and developing novel small molecule therapeutics in cancer, today announced the commencement of patient dosing in its first Phase 1 study of CB-839 in patients with advanced solid tumors. CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase that interferes with tumor metabolism and blocks cancer cell growth and...

2013-12-11 08:30:26

Penetration of Avastin in Multiple Market Segments and Approval of Seven Novel Premium-Priced Therapies Will Drive Market Growth, According to Findings from Decision Resources BURLINGTON, Mass., Dec. 11, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Genentech/Chugai's Avastin will penetrate nearly all segments of the ovarian cancer market through 2022, driving growth of the...

2013-11-29 14:37:54

A study led by researchers at Boston University School of Medicine (BUSM) demonstrates a new mechanism involving a signaling protein and its receptor that may block the formation of new blood vessels and cancer growth. The findings are published in the December issue of Science Signaling. Angiogenesis creates new blood vessels in a process that can lead to the onset and progression of several diseases such as cancer and age-related macular degeneration. Vascular endothelial growth...

2013-07-29 08:25:39

ROCKVILLE, Md., July 29, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today that it has initiated a crossover bioavailability and food effect study of ENMD-2076. The study is a single-blind, randomized, single-dose, crossover study with a food effect arm to investigate the safety and relative bioavailability of two dosage forms of ENMD-2076 administered as...

2013-06-27 08:29:19

ROCKVILLE, Md., June 27, 2013 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today that it has submitted a new drug global clinical trial application with the China Food and Drug Administration (CFDA) for its proprietary oncology drug candidate, ENMD-2076. The purpose of the application is to expand the Company's Phase 2 clinical trial in advanced/metastatic sarcoma...

2013-06-03 08:27:34

- Data accepted as late-breaking, oral presentation at ASCO 2013 RIDGEFIELD, Conn., June 3, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced results from the Phase III LUME-Lung 1 study showing that the addition of the investigational oncology compound nintedanib* to docetaxel improved progression-free survival (PFS) - the primary endpoint - as a second-line treatment in patients with advanced non-small cell lung cancer (NSCLC) compared...

2013-06-03 08:27:18

New trial results presented at American Society of Clinical Oncology (ASCO) 2013 represent first advance in almost a decade in overall survival for patients where initial chemotherapy has failed BURLINGTON, ON, June 3, 2013 /CNW/ - New research on Canada's number one cancer killer(1) is further proof that patients need personalized treatments targeted to their specific type of lung cancer for better outcomes.  Boehringer Ingelheim (Canada) Ltd. today announced highly anticipated...

2013-05-16 08:27:05

Data Presented at American Society of Clinical Oncology (ASCO) on two Boehringer Ingelheim Phase III Oncology Compounds, Afatinib* and Nintedanib*, Show Progression Free Survival in Patients with Advanced Non-Small Cell Lung Cancer BURLINGTON, ON, May 16, 2013 /CNW/ - New research taking place right here on Canadian soil is shedding light on the nation's number one cancer killer,(i) lung cancer.  Boehringer Ingelheim (Canada) Ltd. today announced data from Phase III clinical...

2013-05-15 20:23:01

For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced data from two Phase III clinical trials involving two different investigational oncology compounds - afatinib* and nintedanib* - in two distinct patient populations with advanced non-small cell lung cancer (NSCLC). Results from both studies will be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in...

2013-05-15 20:22:55

For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced the upcoming presentation of data from 14 abstracts involving three of the company's investigational oncology compounds - afatinib*, nintedanib* and volasertib*. Results - to be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2013 - are from Boehringer Ingelheim's robust...